RECRUITINGOBSERVATIONAL

Sex and Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis

Sex Matters: Sex- And Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis (SAGE-PsA) - an International Multicentre Study

About This Trial

Sex and gender are important factors that influence treatment response in PsA. The goal of this multi-centre observational study is to understand how sex and gender influence response to advanced therapies in psoriatic arthritis (PsA). The investigators hope to discover biological and socio-cultural mechanisms that explain the differences in treatment response between men and women with PsA. The study investigators plan to recruit patients from approximately 30 sites across the world. Men and women with active PsA will be assessed before and after they start advanced therapies and information will be collected about sex- and gender-related factors through questionnaires and physical examination. Physicians will assess the patient response to treatment. The investigators will compare the response to treatment in men and women and assess what biological and socio-cultural factors contribute to differences in treatment response.

Who May Be Eligible (Plain English)

Who May Qualify: - Rheumatologist confirmed diagnosis of PsA according to CASPAR criteria - Age ≥18 years - Active PsA with any of the following manifestations detected on physical examination: peripheral arthritis, dactylitis, and enthesitis. The patient may have axial involvement in addition to the peripheral manifestations of PsA - Plan to start treatment with advanced therapies for peripheral musculoskeletal manifestations of PsA Who Should NOT Join This Trial: - Unable to read or write - Unable to sign willing to sign a consent form - Cannot return for a follow up visit - The drug is given for another indication and not for active PsA (e.g. psoriasis, IBD) - Pregnant women Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Rheumatologist confirmed diagnosis of PsA according to CASPAR criteria * Age ≥18 years * Active PsA with any of the following manifestations detected on physical examination: peripheral arthritis, dactylitis, and enthesitis. The patient may have axial involvement in addition to the peripheral manifestations of PsA * Plan to start treatment with advanced therapies for peripheral musculoskeletal manifestations of PsA Exclusion Criteria: * Unable to read or write * Unable to sign informed consent * Cannot return for a follow up visit * The drug is given for another indication and not for active PsA (e.g. psoriasis, IBD) * Pregnant women

Locations (1)

Women's College Hospital

Toronto, Ontario, Canada